The global orthobiological products market is expected to grow with a double digit CAGR of 10% during the forecast period. Development is significantly ascribed to the rising incidences of joint and orthopedic dislocations. Rising worldwide geriatric patient base and growing outdoor activities combined with accidents are other important drivers for the business sector. Rising prevalence of osteoporosis, rheumatoid arthritis and obesity needs therapeutic consideration and surgeries by utilizing orthobiological products is another major factor which is anticipated to boost the market growth during the forecast period. Rising demand for non-intrusive or minimally invasive surgeries is expected to provide new opportunities for technological innovations in the market which further makes new roads for development. Other effect rendering drivers includes demographic and social changes in lifestyle of people, rising spending power of people over healthcare, and rising disposable income. The various benefits provided by orthobiological products, for example, reduced pain and faster healing and recovery are some other factors that are expected to fuel the development of the market further.
The market is facing certain restraint such as high cost associated with the products. The products has high costs, which are beyond the affordability of some people which is restricting the growth of the market. The market has lots of potential opportunities with the rising demand from emerging markets such as china, India, Brazil, etc., rising healthcare spending by people across geographies and growing medical tourism. The market is faced by a major challenge, i.e., the dearth of skilled professionals.
The segments of the orthobiological products market are based on applications, products, and region. The product market segment consist of DBM (Demineralized Bone Matrix), allograft, machined bones, BMP (Bone Morphogenetic Protein), viscosupplementation, machined bones, stem cell therapy, and other applications. Viscosupplementation holds the highest market share and is projected to maintain the current growth path during the forecast period. Rising popularity of viscosupplementation over other products is because of their superior performance and advantages perceived by the patients. Viscosupplements are witnessed to offer long lasting pain relief than other treatments. The rapidly growing segment in products segment is estimated to be of the stem cell therapy. The driving forces for this growth are estimated to be advantages such as improved healing process, reduction in cost of treatment, and fast recovery time.
On the basis of applications, the market is segmented into reconstructive surgeries, trauma, spinal fusion, tendon & ligament repair, and other applications. Spinal fusion holds the largest market share and is estimated to maintain its position during the forecast period. The factors helping the growth are growing aging population that requires the spinal fusion surgeries and the rising prevalence of spinal injuries. Reconstructive surgeries are estimated to show the fastest growth in the application segment due to growing popularity of cosmetic treatments and technological innovations.
Geographically, North America is the leading region in the orthobiological products market. The market expansion and the lead is estimated to sustain during the forecast period owing to the rising population base of geriatric patients, increasing medical device sales, increasing prevalence of injuries, and rising number of orthopedic procedures. Another factor contributing to the higher growth of the region is the growing prevalence of orthopedic disorders such as rheumatoid arthritis and osteoporosis. Europe has the second largest share in the market and is estimated to maintain its place over the forecast period. Germany is estimated to be the country to show huge growth in Europe due to the presence of multiple healthcare companies, rising awareness level of patients regarding orthobiological products and growing geriatric population base. Asia Pacific is expected to be the fastest growing region with particular emphasis on South Korea, China, Malaysia and India. The drivers for the lucrative growth in the region are attributed to the growing disposal income of people, rising spending power of the patients over healthcare, growing medical tourism to these nations, and increasing awareness level of the patients. Technological innovations and government initiatives are estimated to further boost the growth of the market in the region with presence of market growth oriented policies and strategies.
Key players overwhelming the orthobiological products business sector are Baxter International, Inc., Bioventus, Pioneer Surgical Technology, Smith and Nephew Plc, Allograft Tissue Systems, DePuySynthes, Inc., Bone Biologics, Inc., Bone Solutions, Inc., Integra Life Sciences Corp., Sanofi, Tissue Banks International, Medtronic, Inc., Osiris Therapeutics, Inc., Globus Medical, Berkeley Advanced Biomaterials, Inc., Stryker Corp, Tissue Genesis, Inc., and others. Acquisition, product launches are the key strategies followed the by companies.
On November 2015, Bioventus acquired BioStructures, to expand their surgical orthobiologics offering. Bioventus, a worldwide leader in orthobiologic solutions has announced it has acquired BioStructures LLC, a marketer and developer of bioresorbable bone graft products for a wide range of orthopedic surgical and spinal applications. The agreement includes the whole portfolio of products and its research and development channels.
1. METHODOLOGY & SCOPE
1.1. RESEARCH METHODOLOGY
1.2. RESEARCH SCOPE & ASSUMPTIONS
1.3. LIST OF DATA SOURCES
2. EXECUTIVE SUMMARY
2.1. GLOBAL ORTHOBIOLOGICAL PRODUCTS INDUSTRY- MARKET SUMMARY & KEY BUYING CRITERIA
2.2. GLOBAL ORTHOBIOLOGICAL PRODUCTS INDUSTRY OUTLOOK
2.3. SEGMENTATION ANALYSIS
2.4. MARKET SIZE AND GROWTH PROSPECTS 2012-2022
2.5. ORTHOBIOLOGICAL PRODUCTS INDUSTRY VALUE CHAIN ANALYSIS
2.6. VENDOR LANDSCAPE
3. INDUSTRIAL ORTHOBIOLOGICAL PRODUCTS MARKET DYNAMICS
3.1.1. MARKET DRIVER ANALYSIS
22.214.171.124. RISING GERIATRIC POPULATION
126.96.36.199. RISING DISPOSABLE INCOME
188.8.131.52. RISING AWARENESS REGARDING ACCEPTANCE OF ORTHOBIOLOGICS
184.108.40.206. TECHNOLOGICAL ADVANCEMENTS
220.127.116.11. RISING NUMBER OF ORTHOPAEDIC RELATED PROCEDURES
18.104.22.168. BENEFITS ASSOCIATED SUCH AS REDUCED PAIN AND FASTER HEALING AND RECOVERY
3.1.2. MARKET RESTRAINT ANALYSIS
22.214.171.124. HIGH COST ASSOCIATED WITH THE PRODUCTS
3.1.3. KEY OPPORTUNITIES
126.96.36.199. RISING DEMAND FROM EMERGING MARKETS
188.8.131.52. RISING HEALTHCARE SPENDING BY PEOPLE ACROSS GEOGRAPHY
184.108.40.206. GROWING MEDICAL TOURISM
3.1.4. KEY CHALLENGES
220.127.116.11 DEARTH OF TRAINED PERSONNEL
3.2. GLOBAL ORTHOBIOLOGICAL PRODUCTS INDUSTRY – PORTER’S FIVE FORCES MODEL
3.3. GLOBAL ORTHOBIOLOGICAL PRODUCTS INDUSTRY – PESTEL ANALYSIS
3.4. GLOBAL ORTHOBIOLOGICAL PRODUCTS – GAP ANALYSIS
4. GLOBAL ORTHOBIOLOGICAL PRODUCTS BY APPLICATION 2012-2022 ($ MILLION)
4.1. GLOBAL ORTHOBIOLOGICAL PRODUCTS MARKET BY RECONSTRUCTIVE SURGERIES 2012-2022 ($ MILLION)
4.2. GLOBAL ORTHOBIOLOGICAL PRODUCTS MARKET BY TRAUMA 2012-2022 ($ MILLION)
4.3. GLOBAL ORTHOBIOLOGICAL PRODUCTS MARKET BY SPINAL FUSION 2012-2022 ($ MILLION)
4.4. GLOBAL ORTHOBIOLOGICAL PRODUCTS MARKET BY TENDON & LIGAMENT REPAIR 2012-2022 ($ MILLION)
4.5. GLOBAL ORTHOBIOLOGICAL PRODUCTS MARKET BY OTHER APPLICATIONS 2012-2022 ($ MILLION)
5. GLOBAL ORTHOBIOLOGICAL PRODUCTS BY PRODUCT 2012-2022 ($ MILLION)
5.1. GLOBAL ORTHOBIOLOGICAL PRODUCTS MARKET BY DBM (DEMINERALIZED BONE MATRIX) 2012-2022 ($ MILLION)
5.2. GLOBAL ORTHOBIOLOGICAL PRODUCTS MARKET BY ALLOGRAFT 2012-2022 ($ MILLION)
5.3. GLOBAL ORTHOBIOLOGICAL PRODUCTS MARKET BY BMP (BONE MORPHOGENETIC PROTEIN) 2012-2022 ($ MILLION)
5.4. GLOBAL ORTHOBIOLOGICAL PRODUCTS MARKET BY VISCOSUPPLEMENTATION 2012-2022 ($ MILLION)
5.5. GLOBAL ORTHOBIOLOGICAL PRODUCTS MARKET BY MACHINED BONES 2012-2022 ($ MILLION)
5.6. GLOBAL ORTHOBIOLOGICAL PRODUCTS MARKET BY STEM CELL THERAPY 2012-2022 ($ MILLION)
5.7. GLOBAL ORTHOBIOLOGICAL PRODUCTS MARKET BY OTHER PRODUCTS 2012-2022 ($ MILLION)
6. GLOBAL ORTHOBIOLOGICAL PRODUCTS INDUSTRY REGIONAL OUTLOOK 2012-2022 ($ MILLION)
6.1. NORTH AMERICA
6.3. ASIA PACIFIC
6.3.3. SOUTH KOREA
6.4. MIDDLE EAST & AFRICA
6.5. CENTRAL &SOUTH AMERICA
7. COMPETITIVE LANDSCAPE
7.1. BAXTER INTERNATIONAL, INC.
7.1.1. COMPANY OVERVIEW
7.1.2. SCOT ANALYSIS
7.1.3. PRODUCT BENCHMARKING
7.1.4. STRATEGIC INITIATIVES
7.2. BERKELEY ADVANCED BIOMATERIALS, INC.
7.2.1. COMPANY OVERVIEW
7.2.2. SCOT ANALYSIS
7.2.3. PRODUCT BENCHMARKING
7.2.4. STRATEGIC INITIATIVES
7.3.1. COMPANY OVERVIEW
7.3.2. SCOT ANALYSIS
7.3.3. PRODUCT BENCHMARKING
7.3.4. STRATEGIC INITIATIVES
7.4. BONE BIOLOGICS, INC.
7.4.1. COMPANY OVERVIEW
18.104.22.168. SCOT ANALYSIS
22.214.171.124. PRODUCT BENCHMARKING
7.4.2. STRATEGIC INITIATIVES
7.5. DEPUY SYNTHES, INC.
7.5.1. COMPANY OVERVIEW
7.5.2. SCOT ANALYSIS
7.5.3. PRODUCT BENCHMARKING
7.5.4. STRATEGIC INITIATIVES
7.6. INTEGRA LIFESCIENCES CORP.
7.6.1. COMPANY OVERVIEW
7.6.2. SCOT ANALYSIS
7.6.3. PRODUCT BENCHMARKING
7.6.4. STRATEGIC INITIATIVES
7.7. INTERVENTIONAL SPINE, INC.
7.7.1. COMPANY OVERVIEW
7.7.2. SCOT ANALYSIS
7.7.3. PRODUCT BENCHMARKING
7.7.4. STRATEGIC INITIATIVES
7.8. MEDTRONIC, INC.
7.8.1. COMPANY OVERVIEW
7.8.2. SCOT ANALYSIS
7.8.3. PRODUCT BENCHMARKING
7.8.4. STRATEGIC INITIATIVES
7.9. OSIRIS THERAPEUTICS, INC.
7.9.1. COMPANY OVERVIEW
7.9.2. SCOT ANALYSIS
7.9.3. PRODUCT BENCHMARKING
7.9.4. STRATEGIC INITIATIVES
7.10. PIONEER SURGICAL TECHNOLOGY
7.10.1. COMPANY OVERVIEW
7.10.2. SCOT ANALYSIS
7.10.3. PRODUCT BENCHMARKING
7.10.4. STRATEGIC INITIATIVES
7.11.1. COMPANY OVERVIEW
7.11.2. SCOT ANALYSIS
7.11.3. PRODUCT BENCHMARKING
7.11.4. STRATEGIC INITIATIVES
7.12. SMITH AND NEPHEW PLC
7.12.1. COMPANY OVERVIEW
7.12.2. SCOT ANALYSIS
7.12.3. PRODUCT BENCHMARKING
7.12.4. STRATEGIC INITIATIVES
7.13. STRYKER CORP.
7.13.1. COMPANY OVERVIEW
7.13.2. SCOT ANALYSIS
7.13.3. PRODUCT BENCHMARKING
7.13.4. STRATEGIC INITIATIVES
7.14. TISSUE BANKS INTERNATIONAL
7.14.1. COMPANY OVERVIEW
7.14.2. SCOT ANALYSIS
7.14.3. PRODUCT BENCHMARKING
7.14.4. STRATEGIC INITIATIVES
7.15. TISSUE GENESIS, INC.
7.15.1. COMPANY OVERVIEW
7.15.2. SCOT ANALYSIS
7.15.3. PRODUCT BENCHMARKING
7.15.4. STRATEGIC INITIATIVES